Nootropic

Selank

Limited human data

A synthetic heptapeptide analogue of the immune peptide tuftsin, again with a Pro-Gly-Pro tail added for stability.

NasalSubQIntermediateApproved outside the USrecovery and sleepfocus and cognitionneuroprotectionimmune support

Also known as TP-7 · Thr-Lys-Pro-Arg-Pro-Gly-Pro · Tuftsin analogue · N-Acetyl Selank Amidate

At a glance

Dose summary

Typical dose300 mcg
Range150 mcg–900 mcg
Frequency2×/day
Half-lifeUnknown
ScheduleTwice daily
Cycle length2 weeks
RouteNasal · SubQ
Experience levelIntermediate
Evidence gradeLimited human data
ApprovalApproved outside the US
Where the dose comes fromCommunity practice, not a trial

No reliable human half-life has been published for Selank, so none is listed rather than guessed at.

No regulator and no trial set these numbers. They describe what people actually do, recorded so you can see the range rather than guess at it — which is not the same thing as a recommendation.

Reconstitution

What to draw, at the usual vial

A 5 mg vial reconstituted with 2 mL of bacteriostatic water gives 2.50 mg/mL. A typical 300 mcg dose is 0.120 mL — pull the plunger to 12 units on a U-100 syringe.

Concentration2.50 mg/mL
Draw volume0.120 mL
U-100 units12 units
Doses per vial16

Same dose, other vial sizes

VialWaterConcentrationDrawUnitsDoses
5 mg2 mL2.50 mg/mL0.120 mL12 units16
10 mg2 mL5.00 mg/mL0.060 mL6 units33

The highlighted row is the one quoted above: the smallest listed vial that holds at least four typical doses. Change any of it — a different vial, more or less water, a different dose — on the reconstitution calculator, which draws the syringe to true U-100 graduations.

Mechanism & evidence

What it is, and what is known

A synthetic heptapeptide analogue of the immune peptide tuftsin, again with a Pro-Gly-Pro tail added for stability. Its character is anxiolytic rather than stimulant, which is why it is usually paired with, not substituted for, Semax. Like Semax it is a Russian-registered intranasal medicine (commonly a 0.15% solution) and is NOT approved in the US or EU; the human evidence is small Russian trials in generalised anxiety disorder and adjustment disorder, some comparing it against benzodiazepines such as phenazepam, and it has not been independently replicated in Western trials.

Route matters: it is an intranasal drug, not an injectable. Russian clinical dosing runs to roughly 1800-2700 mcg per day divided across two or three administrations; the per-dose range here reflects the more conservative doses typical of non-clinical use rather than the full trial daily total. Plasma half-life is minutes, so no hourly figure is listed. Courses are conventionally short (10-14 days) rather than continuous.

The caveat

Small Russian trials, never independently replicated in Western trials. Registered in Russia only.

Tolerability

Reported side effects

  • Nasal stinging or irritation at the spray site
  • Drowsiness or blunted drive, more likely at the top of the range
  • Mild headache
  • Bitter taste or post-nasal drip after spraying

Hard stops

Do not use this if

  • Pregnancy, possible pregnancy, or breastfeeding
  • Under 18

These are flags, not a screening. They do not replace a conversation with a clinician who knows your history.

Handling

Storage

Sealed powder, refrigerated24 months
After reconstitution, refrigerated30 days

Keep it cold, keep it dark, and label the vial with the date you mixed it. Discard anything cloudy or past the window above.

Combinations

Commonly stacked with

Stacking multiplies the side-effect surface and makes it impossible to tell which compound did what. Add one thing at a time.

Where it shows up

Protocols using this compound

References

Sources

Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.